Pro-Pharmaceuticals, Inc. is engaged in the discovery, development and commercialization of therapeutics that target Galectin receptors for the advanced treatment of cancer. Today, Pro-Pharmaceuticals took a major step with the announcement they have collaborated with Numoda to manage the Phase III clinical trial of DAVANAT®.
The combination of Pro-Pharmaceuticals and Numoda appears to be a winning one. DAVANAT is Pro-Pharmaceuticals’ lead product candidate and has excelled with the 100 cancer patients it was tested on. As for Numoda, the company is regarded as the world’s most innovative and complete technology solutions provider in the life sciences industry.
When asked what this collaboration will mean to the future of Pro-Pharmaceuticals and potentially to cancer patients, Theodore Zucconi, PhD who serves as the company’s CEO was quoted as saying, “With this collaboration, we will optimize both time and cost, which we believe will provide us positive results, faster, in the continued path to a New Drug Application (NDA) for our DAVANAT(R) compound. By engaging Numoda for the management of the trial data and subcontractors, we believe the data accuracy and time for analysis will be significantly less.”
The Phase III clinical trial of DAVANAT has the potential to lead to a revolution in the industry and benefit both cancer patients and investors. Currently, Pro-Pharmaceuticals is trading in the $0.65 range. With this breaking news and strong corporate management, many pundits expect this company to make a significant impression on the cancer treatment industry.
To learn more about Pro-Pharmaceuticals, Inc., visit the company website at: www.pro-pharmaceuticals.com.
Let us hear your thoughts below: